宠物用癌症治疗的全球市场 - 产业规模,占有率,趋势,机会,预测:各治疗法,各动物类型,各癌症类型,各企业,各地区(2017年~2027年)
市场调查报告书
商品编码
1152253

宠物用癌症治疗的全球市场 - 产业规模,占有率,趋势,机会,预测:各治疗法,各动物类型,各癌症类型,各企业,各地区(2017年~2027年)

Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Animal Type, By Cancer Type, By Company, and By Region

出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球宠物用癌症治疗的市场规模,预计在预测期间内的2023年~2027年达成惊人的成长。

市场成长的主要原因,是对宠物健康的意识高涨,和动物的癌症发病率增加。还有市场成长的其他的因素,是拥有的宠物率、动物饲养数的扩大,诊断技术的进步,研究开发举措增加等。再加上宠物的肿瘤学治疗对管理相关研究开发活动的高额的投资,预计今后数年提供向市场企业有利的机会。

本报告提供全球宠物用癌症治疗市场相关调查分析,各市场区隔、各地区的市场规模、占有率预测,市场动态,企业简介等系统性资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 COVID-19对全球宠物用癌症治疗市场的影响

第5章 VOC(客户的迴响)

第6章 全球宠物用癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法(手术,放射线治疗,化疗,免疫疗法,其他)
    • 各动物类型(狗,猫,其他)
    • 各癌症类型(淋巴瘤,肥胖细胞癌症,乳腺、扁平表皮癌症,其他)
    • 各企业(2021年)
    • 各地区
  • 市场地图

第7章 北美的宠物用癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法
    • 各动物类型
    • 各癌症类型
    • 各国
  • 北美:各国分析
    • 美国
    • 墨西哥
    • 加拿大

第8章 欧洲的宠物用癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法
    • 各动物类型
    • 各癌症类型
    • 各国
  • 欧洲:各国分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第9章 亚太地区的宠物癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法
    • 各动物类型
    • 各癌症类型
    • 各国
  • 亚太地区:各国分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第10章 南美的宠物用癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法
    • 各动物类型
    • 各癌症类型
    • 各国
  • 南美:各国分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第11章 中东、非洲的宠物用癌症治疗市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗法
    • 各动物类型
    • 各癌症类型
    • 各国
  • MEA:各国分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 土耳其

第12章 市场动态

  • 促进因素
  • 课题

第13章 市场趋势与开发

第14章 竞争情形

  • C.H. Boehringer Sohn Ko. KG
  • ELIAS Animal Health, LLC
  • Zoetis Inc.
  • AB Science S.A.
  • Karyopharm Therapeutics, Inc.
  • Vivesto AB
  • Merial Inc.
  • Elanco Animal Health, Inc.
  • Dechra Pharmaceuticals PLC(Anivive Lifesciences)
  • Torigen Pharmaceuticals Inc.

第15章 策略性建议

简介目录
Product Code: 12985

The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet's health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.

Increasing Awareness regarding Pet Healthcare and Treatments

The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet's health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet's health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.

Increasing Prevalence of Cancer

The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.

Technological Advancements

Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet's body.

Market Segmentation

The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.

Market Players

C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Pet Cancer Therapeutics Market, By Therapy:

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Others

Pet Cancer Therapeutics Market, By Animal Type:

  • Canine
  • Feline
  • Others

Pet Cancer Therapeutics Market, By Cancer Type:

  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer
  • Others

Pet Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Pet Cancer Therapeutics Market

5. Voice of Customer

6. Global Pet Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
    • 6.2.2. By Animal Type (Canine, Feline, Others)
    • 6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
    • 6.2.4. By Company (2021)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Pet Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Animal Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Pet Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Animal Type
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Animal Type
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. Canada Pet Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Animal Type
        • 7.3.3.2.3. By Cancer Type

8. Europe Pet Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Animal Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Pet Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Animal Type
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. Germany Pet Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Animal Type
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Animal Type
        • 8.3.3.2.3. By Cancer Type
    • 8.3.4. Italy Pet Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Animal Type
        • 8.3.4.2.3. By Cancer Type
    • 8.3.5. Spain Pet Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Animal Type
        • 8.3.5.2.3. By Cancer Type

9. Asia-Pacific Pet Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Animal Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Pet Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Animal Type
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. India Pet Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Animal Type
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. Japan Pet Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Animal Type
        • 9.3.3.2.3. By Cancer Type
    • 9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Animal Type
        • 9.3.4.2.3. By Cancer Type
    • 9.3.5. Australia Pet Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Animal Type
        • 9.3.5.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Animal Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Animal Type
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Animal Type
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Animal Type
        • 10.3.3.2.3. By Cancer Type

11. Middle East and Africa Pet Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Animal Type
    • 11.2.3. By Cancer Type
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Animal Type
        • 11.3.1.2.3. By Cancer Type
    • 11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Animal Type
        • 11.3.2.2.3. By Cancer Type
    • 11.3.3. UAE Pet Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Animal Type
        • 11.3.3.2.3. By Cancer Type
    • 11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Therapy
        • 11.3.4.2.2. By Animal Type
        • 11.3.4.2.3. By Cancer Type
    • 11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Therapy
        • 11.3.5.2.2. By Animal Type
        • 11.3.5.2.3. By Cancer Type

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. C.H. Boehringer Sohn Ko. KG
  • 14.2. ELIAS Animal Health, LLC
  • 14.3. Zoetis Inc.
  • 14.4. AB Science S.A.
  • 14.5. Karyopharm Therapeutics, Inc.
  • 14.6. Vivesto AB
  • 14.7. Merial Inc.
  • 14.8. Elanco Animal Health, Inc.
  • 14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
  • 14.10. Torigen Pharmaceuticals Inc.

15. Strategic Recommendations